Crystal form of imidazolone type compounds, and preparation method, pharmaceutical composition and use thereof

A crystal of a pharmaceutically acceptable salt of Compound 1 represented by the following formula or a hydrate thereof:

• wherein
• (a) said crystal is Crystal Form I of Compound 1 hydrochloride monohydrate, which is characterized by an X-ray powder diffraction pattern obtained by using Cu-Kα radiation, which diffraction pattern comprises characteristic peaks expressed in 2-theta angle (°) at:
• 9.028±0.2, 11.196±0.2, 17.393±0.2, 22.504±0.2;
• or
• 9.028±0.2, 11.196±0.2, 15.406±0.2, 16.380±0.2, 17.393±0.2, 18.066±0.2, 18.739±0.2, 20.894±0.2, 22.504±0.2, 22.955±0.2;
• or
• 9.028±0.2, 11.196±0.2, 15.406±0.2, 16.380±0.2, 17.393±0.2, 18.066±0.2, 18.739±0.2, 20.894±0.2, 22.504±0.2, 22.955±0.2, 26.312±0.2, 26.918±0.2, 27.556±0.2, 35.168±0.2;
• or
• 9.028±0.2, 11.196±0.2, 12.200±0.2, 15.406±0.2, 16.380±0.2, 16.828±0.2, 17.393±0.2, 18.066±0.2, 18.739±0.2, 20.036±0.2, 20.894±0.2, 22.504±0.2, 22.955±0.2, 24.973±0.2,
• 25.505±0.2, 26.312±0.2, 26.918±0.2, 27.556±0.2, 28.403±0.2, 29.176±0.2, 31.586±0.2, 35.168±0.2;
• or
• (b) said crystal is Crystal Form II of Compound 1 hydrochloride monohydrate, which is characterized by an X-ray powder diffraction pattern obtained by using Cu-Kα radiation, which diffraction pattern comprises characteristic peaks expressed in 2-theta angle (°) at:
• 8.934±0.2, 11.126±0.2, 15.367±0.2, 22.437±0.2;
• or
• 8.934±0.2, 11.126±0.2, 12.161±0.2, 15.367±0.2, 16.289±0.2, 17.369±0.2, 18.037±0.2, 18.667±0.2, 20.896±0.2, 22.437±0.2, 22.928±0.2, 24.995±0.2, 26.269±0.2, 26.890±0.2, 27.574±0.2;
• or
• 8.486±0.2, 8.934±0.2, 11.126±0.2, 12.161±0.2, 13.317±0.2 15.367±0.2, 16.289±0.2, 16.742±0.2, 17.369±0.2, 18.037±0.2, 18.667±0.2, 19.966±0.2, 20.896±0.2, 22.437±0.2, 22.928±0.2, 24.995±0.2, 25.467±0.2, 26.269±0.2, 26.890±0.2, 27.213±0.2, 27.574±0.2, 28.366±0.2, 29.075±0.2, 35.001±0.2;
• or
• (c) said crystal is Crystal Form III of Compound 1 hydrochloride, which is characterized by an X-ray powder diffraction pattern obtained by using Cu-Kα radiation, which diffraction pattern comprises characteristic peaks expressed in 2-theta angle (°) at:
• 6.396±0.2, 7.115±0.2, 8.972±0.2, 10.803±0.2, 11.870±0.2, 18.542±0.2, 23.071±0.2;
• or
• 6.396±0.2, 7.115±0.2, 8.972±0.2, 10.803±0.2, 11.147±0.2, 11.870±0.2, 12.139±0.2, 15.417±0.2, 16.297±0.2, 16.559±0.2, 17.374±0.2, 18.074±0.2, 18.542±0.2, 19.310±0.2, 22.464±0.2, 23.071±0.2, 24.550±0.2, 25.843±0.2, 26.903±0.2, 28.737±0.2, 29.664±0.2, 35.016±0.2;
• or
• (d) said crystal is Crystal Form IV of Compound 1 hydrochloride, which is characterized by an X-ray powder diffraction pattern obtained by using Cu-Kα radiation, which diffraction pattern comprises characteristic peaks expressed in 2-theta angle (°) at:
• 6.178±0.2, 8.996±0.2, 11.170±0.2, 15.393±0.2, 16.343±0.2, 17.349±0.2, 18.064±0.2, 18.708±0.2, 19.479±0.2, 19.994±0.2, 20.901±0.2, 22.470±0.2, 22.935±0.2, 24.964±0.2, 25.504±0.2, 26.287±0.2, 26.920±0.2, 27.545±0.2;
• or
• 6.178±0.2, 6.614±0.2, 7.181±0.2, 7.470±0.2, 8.996±0.2, 11.170±0.2, 11.723±0.2, 12.183±0.2, 13.323±0.2, 14.412±0.2, 15.393±0.2, 16.343±0.2, 16.777±0.2, 17.349±0.2, 18.064±0.2, 18.708±0.2, 19.479±0.2, 19.994±0.2, 20.901±0.2, 22.470±0.2, 22.935±0.2, 24.964±0.2, 25.504±0.2, 26.287±0.2, 26.920±0.2, 27.545±0.2, 28.363±0.2, 28.841±0.2, 29.152±0.2, 31.487±0.2, 33.970±0.2, 35.136±0.2;
• or
• (e) said crystal is Crystal Form V of Compound 1 hydrochloride dihydrate, which is characterized by an X-ray powder diffraction pattern obtained by using Cu-Kα radiation, which diffraction pattern comprises characteristic peaks expressed in 2-theta angle (°) at:
• 6.181±0.2, 8.318±0.2, 18.223±0.2, 31.778±0.2;
• or
• 6.181±0.2, 7.226±0.2, 8.318±0.2, 9.524±0.2, 10.496±0.2, 12.037±0.2, 18.223±0.2, 27.421±0.2, 31.778±0.2;
• or
• (f) said crystal is Crystal Form VI of Compound 1 hydrochloride dihydrate, which is characterized by an X-ray powder diffraction pattern obtained by using Cu-Kα radiation, which diffraction pattern comprises characteristic peaks expressed in 2-theta angle (°) at:
• 7.489±0.2, 8.897±0.2, 11.140±0.2, 11.638±0.2, 13.348±0.2, 13.755±0.2, 16.110±0.2, 17.152±0.2, 18.782±0.2, 19.865±0.2, 20.891±0.2, 21.477±0.2, 25.245±0.2, 26.184±0.2, 26.431±0.2, 27.242±0.2, 28.489±0.2;
• or
• 7.489±0.2, 8.153±0.2, 8.897±0.2, 11.140±0.2, 11.638±0.2, 13.348±0.2, 13.755±0.2, 14.985±0.2, 15.467±0.2, 16.110±0.2, 17.152±0.2, 18.240±0.2, 18.782±0.2, 19.865±0.2, 20.891±0.2, 21.477±0.2, 22.333±0.2, 22.888±0.2, 25.245±0.2, 26.184±0.2, 26.431±0.2, 27.242±0.2, 28.489±0.2, 29.710±0.2;
• or
• (g) said crystal is Crystal Form VII of Compound 1 hydrochloride dihydrate, which is characterized by an X-ray powder diffraction pattern obtained by using Cu-Kα radiation, which diffraction pattern comprises characteristic peaks expressed in 2-theta angle (°) at:
• 6.264±0.2, 6.760±0.2, 7.556±0.2, 14.455±0.2, 20.123±0.2, 26.373±0.2;
• or
• 6.264±0.2, 6.760±0.2, 7.556±0.2, 11.414±0.2, 11.743±0.2, 12.488±0.2, 13.419±0.2, 14.455±0.2, 17.246±0.2, 18.099±0.2, 20.123±0.2, 21.082±0.2, 25.370±0.2, 26.373±0.2, 27.294±0.2.